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Chimeric RNA/DNA oligonucleotide-based gene therapy. tors not only prevent long-term expression of therapeutic
Background. Chimeric RNA/DNA oligonucleotides, emerg- genes, but also result in serious complications. Retroviral
ing as a potential strategy for gene therapy, have been shown vectors may cause random integration and disrupt the nor-to induce site-specific correction of point mutations in several
mal genes. Nonviral vectors such as liposomes and poly-genetic disease models.
cations are not able to achieve stable long-term gene ex-Methods. Six recent studies of chimeric RNA/DNA oligo-
nucleotide-based gene therapy in genetic disease models are pression [3–6]. In addition, a full-length cDNA is required
reviewed. Chimeric RNA/DNA oligonucleotides, complemen- to construct the therapeutic genes, which is a problem
tary to 25 to 30 residues of genomic DNA flanking the mutation especially for a gene with large transcripts. Furthermore,site with the exception of a mismatch in the center, were deliv-
the transfected genes may not have the appropriate tran-ered via different routes and delivery vehicles to target differ-
scriptional regulatory machinery, which is critical for cellent tissues and organs. Corrections of the mutation at genotypic
and phenotypic levels were assessed using various methods, specificity and proper function of the transgenes.
including allele-specific polymerase chain reaction assay, re- Recently, a novel strategy to correct a point mutation
striction enzyme digestion, colony-lifting assays, sequencing, using a chimeric RNA/DNA oligonucleotide has beenNorthern and Western blot analyses, enzyme activity assay,
reported [7–9]. This strategy evolved from the findingimmunohistochemical staining, and functional studies.
that RNA/DNA hybrids were more active in homolo-Results. The gene correction frequency varied, ranging from
less than 1% to more than 40%. This represented several mag- gous pairing reactions in vitro than corresponding DNA
nitudes higher conversion rate compared with homologous re- [10–12]. Based on this finding, a chimeric RNA/DNA
combination frequency, which is in the range of 105 to 106. oligonucleotide, containing one DNA strand aligning toThe resulting phenotype changes lasted longer than one year
25 residues of genomic DNA flanking the site of muta-in some studies.
tion with the exception of a single mismatched nucleotideConclusion. Chimeric RNA/DNA oligonucleotide-based gene
therapy has the potential to develop into powerful therapeutic located at the center and one complementary RNA/
modality for genetic diseases. It can offer permanent expression DNA hybrid strand with two blocks of 10 2-O-methyl-
and normal regulation of corrected genes in appropriate cells or ated RNA residues flanking both sides of a five-residuetissues. Further efforts to elucidate the mechanisms of chimeric
stretch of DNA, was created (Fig. 1). The folded double-RNA/DNA oligonucleotide-based gene therapy are warranted
hairpin structure, containing four T residues in each loop,in order to increase the efficacy and safety of this method.
a 5 bp guanine-cytosine (GC) clamp, and the modified
RNA residues, was designed to improve resistance to
nuclease degradation. The alignment of the chimericMost of the current strategies for gene therapy are
molecule with the genomic site appears to trigger anbased on the delivery of therapeutic genes using viral or
endogenous repair system that facilitates homologousplasmid vectors in vivo and ex vivo. With a few excep-
conversion. The mechanism of gene correction seems totions, such as severe combined immune deficient syn-
involve both homologous pairing and mismatch repairdrome [1], the results of most expression vector-based
activities [13]. Cole-Strauss et al recently reported thatgene therapy trials for genetic diseases have been disap-
chimeric RNA/DNA oligonucleotide-mediated gene re-pointing. Severe complications, including one death [2],
pair in mammalian cell-free extracts from the HuH-7have led the public to doubt the values of gene therapy
hepatoma cell line depended on the presence of mis-and investigators in this field to re-examine their strate-
match repair enzyme MSH2 protein [14]. Different levelsgies. The immune reactions induced by adenoviral vec-
of endogenous mismatch repair activities among differ-
ent cell types may explain some of the variation in the
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tissues. Gamper et al have shown that the DNA strandtype I, UDP-glucuronosyltransferase, Duchenne muscular dystrophy,
dystrophin. but not the chimeric strand of the chimeric RNA/DNA
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Fig. 1. Sequence of the normal and CA II
() alleles and chimeric RNA/DNA oligonu-
cleotide. The site of mutation is underlined.
The chimeric oligonucleotide contains 25 ho-
mologous DNA residues identical to normal
allele and only one bp different from CA II
() allele. The antisense strand contains five
core DNA residues that is flanked by 10 2-O-
methyl RNA residues at each side. A double-
hairpin configuration is also included. DNA
residues are capitalized, and 2-O-methyl RNA
residues are in lowercase.
Table 1. Disease models tested using chimeric RNA/DNA oligonucleotide based gene therapy
Disease Gene Tissue/cell type Vehicle References
Fabry disease -Galatosidase A Lymphoblast Effectene [19]
CA II deficiency CA II Renal tubule PEI [20]
Albinism Tyrosinase Melanocyte Cytofectin [22]
Crigler-Najjar syndrome type I UGT1A1 Liver L-PEI and liposome [23]
Duchenne muscular dystrophy Dystrophin Muscle None [24, 25]
Abbreviations are: PEI, polyethylenimine; UGT1A1, UDP-glucuronosyltransferase; CA II, Carbonic Anhydrase II; L-PEI, Lactosylated PEI.
gene correction when one of its bases was mismatched characterized by skin lesions and involvement of heart,
to the target gene [15]. The role of the chimeric strand central nerve system, blood vessels, and kidneys. We
appeared to be facilitating the complex formation with have identified a family of patients with Fabry disease.
the target, thus increasing the frequency of gene conver- Reverse transcription-polymerase chain reaction (RT-
sion. PCR) sequencing of the peripheral lymphocyte RNA
The feasibility of this oligonucleotide-based gene ther- from all female carriers and a male patient reveals a C
apy was tested in an in vitro system of sickle cell anemia to T mutation, resulting in an amino acid substitution of
[16] and human hepatoma cell line HuH-7 [17]. After Pro-40 by Ser. The serum-galactosidase A activity from
introduction of the chimeric molecule into lymphoblas- the male patient was undetectable, and the lymphocyte
toid cells homozygous for the S mutation, conversion -galactosidase A activity was less than 10% of the nor-
of the mutant allele to the normal sequence was con- mal value. We transfected the chimeric RNA/DNA oli-
firmed by direct sequencing of the polymerase chain
gonucleotides with the correct sequence into culturedreaction (PCR)-amplified fragment [16]. In the hepa-
peripheral lymphocytes and EB virus-transformed lympho-toma cell line system, a single base pair mutation in
blasts from the male patient [19]. The conversion ofthe alkaline phosphatase gene was introduced following
mutant T to C was confirmed by allele-specific PCR assaypolyethylenimine (PEI) transfection with the chimeric
on the genomic DNA. The treatment increased the -molecule [17]. The overall frequency of conversion was
galactosidase enzymatic activity from baseline 9.2 up to 11.9%, and when corrected for transfection effi-
0.7% and 8.5  1.6% (of the normal value) to 15.0 ciency, it approached 43%. Subsequently, Kren et al
2.1% and 20.9  4.9% in cultured peripheral lympho-reported the first in vivo study using lactosylated 25 kD
PEI as a delivery system specific to the liver and were cytes and EB virus-transformed lymphoblasts, respec-
able to mutate factor IX gene to prolong the activated tively. Potentially, this gene therapy strategy can be used
partial thromboplastin time by 25% and achieve up to to treat Fabry disease in this family.
40% conversion in rat liver cells when the rats were
injected twice [18]. Since then, several groups have re-
IN VIVO CORRECTION OF THE CARBONICported a successful chimeric RNA/DNA oligonucleotide-
ANHYDRASE II MUTATION IN CARBONICbased gene therapy in various genetic disease models.
ANHYDRASE II-DEFICIENT MICEThese technologies and respective results are summa-
rized in Table 1 and are reviewed as follows. The carbonic anhydrase (CA) II-deficient mouse
model was used to test the feasibility of gene therapy
CORRECTION OF A POINT MUTATION using the chimeric RNA/DNA oligonucleotides. The
IN -GALACTOSIDASE A GENE mutation is caused by a point mutation in amino acid
IN FABRY LYMPHOBLASTS codon 154, converting Gln (CAA) to a stop codon
(TAA). Previously, we have shown that liposome-medi-Fabry disease is an X-linked recessive disease, caused
by a defective lysosomal enzyme, -galactosidase A, ated gene therapy is sufficient to correct renal tubular
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acidosis; however, the gene expression was transient [6]. If the number of the corrected melanocytes is under the
threshold, the phenotypic change may not be observed.The chimeric RNA/DNA oligonucleotide (Oligo-CA)
was complexed with PEI and injected intravenously in
adult CA II-deficient mice. Replacement of the mutant
CORRECTION OF A SINGLE BASE
sequence by the exogenous normal sequence at the ap-
PAIR DELETION IN THE UDP-
propriate genomic locus, and the resulting expression of GLUCURONOSYLTRANSFERASE
the wild-type gene product was confirmed by RT-PCR GENE IN THE GUNN RAT MODEL
sequencing, allele-specific PCR assay, Northern blot OF CRIGLER-NAJJAR SYNDROME TYPE I
analysis, and Western blot analysis [20]. The mutation
For the first time, Kren et al have successfully shownconversion lasted for at least six months, and the conver-
that chimeric RNA/DNA oligonucleotide-based genesion rate was improved by repeated intravenous injection
therapy can correct a single base pair deletion in vivo(unpublished data). In addition, we investigated whether
[23]. A single guanosine (G) base deletion in UDP-glucu-unwanted mutation to the nontargeting sequence would
ronosyltransferase gene (UGT1A1) resulted in a frame-occur after the chimeric RNA/DNA oligonucleotide
shift and a premature stop codon, lack of enzyme activity,gene targeting [21]. After BLAST genome database
and hyperbilirubinemia in Gunn rat. A slightly longersearch, we identified a mouse gene, regucalcin, which is
chimeric oligonucleotide (28 bp sequence homology tohighly homologous to the target sequence. We synthe-
the target gene except the inserted G base) was eithersized a 97 bp putative mutation sequence of regucalcin
complexed with PEI or encapsulated in anionic lipo-gene containing the homologous region and developed
somes, administered intravenously, and targeted to thean allele-specific PCR assay to detect the putative muta-
hepatocyte via the asialoglycoprotein receptor. G inser-
tion sequence. After gene targeting with Oligo-CA in
tion was determined by PCR amplification, colony lift
cultured CA II-deficient renal tubular cells, the genomic
hybridizations, restriction endonuclease digestion, DNA
DNA was isolated and subjected to allele-specific PCR sequencing, and genomic Southern blot analysis. DNA
for both CA II and regucalcin. The gene conversion rate repair was stable throughout the six-month observation
for CA II was 1 to 5%, whereas no point mutation in period and was associated with a reduction of serum
the regucalcin gene was detected. Our data suggest that bilirubin levels. The data indicate that correction of the
gene targeting by chimeric RNA/DNA oligonucleotides UGT1A1 genetic lesion in the Gunn rat restores enzyme
is feasible to correct the mutation in CA II gene and is expression and bilirubin conjugating activity, resulting
highly sequence specific. in improvement in the metabolic abnormality. The time
course for hepatic disappearance of the fluorescein label
in rats injected with the liposome or PEI complexedCORRECTION OF THE TYROSINASE GENE
chimeric RNA/DNA oligonucleotides was also charac-MUTATION IN ALBINO BALB/c MOUSE SKIN
terized. The fluorescence level was stable until 24-hoursAlexeev et al reported that the detection of pigmented
postinjection and decreased dramatically throughout the
hairs in approximately 50% of animals received either
liver by 48 hours. By 120 to 168 hours, there was only
topical application or intradermal injection of the RNA-
background fluorescence. Disappearance of the fluores-
DNA oligonucleotide designed to correct a point muta- cein label in the other tissues was similar to that observed
tion in tyrosinase gene [22]. Active tyrosinase was de- in the liver.
tected in skin sections three months after the last treat-
ment with chimeric oligonucleotide, which corresponds
CORRECTION OF DYSTROPHIN GENEwith more than one hair cycle. The gene correction may
MUTATION IN CANINE MODEL OFalso occur in precursor melanocytes, as suggested by
DUCHENNE MUSCULAR DYSTROPHYthe prolonged expression of tyrosinase activity found in
some hairs. The frequency of gene correction at the A point mutation within the splice acceptor site of
phenotypic level, as demonstrated by the number of dark intron 6 leads to deletion of exon 7 from the dystrophin
pigmented hairs and DOPA-positive hair follicles, ap- mRNA and results in frame shift that causes early termi-
peared to be much lower than the frequency of chromo- nation of translation. Bartlett et al have demonstrated
somal DNA sequence correction observed from the same in vivo repair of the dystrophin gene mutation by direct
skin biopsy. A likely explanation is that phenotypic skeletal muscle injection of the chimeric oligonucleotide
change is exclusively caused by melanocytes, which com- into the cranial tibialis compartment of a six-week-old
pose less than 1% of total cells in skin, whereas genotypic affected male dog [24]. Analysis of biopsy and necropsy
change is measured in all cells in skin biopsy. It is also samples suggested that the repair was sustained for 48
possible that gene correction of multiple melanocytes weeks. RT-PCR analysis of exons 5 to 10 demonstrated
increasing levels of exon 7 inclusion with time. Synthesisper hair follicle may be required for hair pigmentation.
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of normal-sized dystrophin product and positive localiza- tide-based gene therapy, a therapeutic gene will be cus-
tion to the sarcolemma was confirmed using an exon tomer made to target the mutation site specifically.
7-specific dystrophin antibody. Chromosomal repair in Recently, the mutated genes and their sequences have
muscle tissue was confirmed by restriction fragment been identified in a variety of genetic renal diseases. The
length polymorphism–PCR and sequencing of the PCR chimeric RNA/DNA oligonucleotide-based gene ther-
product. This work supports evidence for the long-term apy may be a promising approach for treating these dis-
repair of a specific dystrophin point mutation in dog eases.
muscle using a chimeric oligonucleotide.
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